
Janux Therapeutics (JANX) Stock Forecast & Price Target
Janux Therapeutics (JANX) Analyst Ratings
Bulls say
Janux Therapeutics is supported by a differentiated tumor-activated masking platform that may solve the core historical limitation of T cell engagers by improving safety while preserving efficacy, with JANX007 emerging as a potentially viable PSMA therapy in mCRPC. The investment case is strengthened by multiple near-term catalysts, including continued enrollment in taxane-naive mCRPC and a key JANX007 update in 1H27, which could show durability competitive with the ~11.5-12m rPFS benchmark set by Pluvicto in PSMAfore. Financially, the company ended 2Q26 with $971m in cash and is viewed as well capitalized, while broader optionality from JANX013, JANX014, and JANX011 plus multiple pharma partnerships could support rerating.
Bears say
Janux Therapeutics is a clinical-stage biopharmaceutical company facing a materially risky path because its outlook hinges on JANX007 delivering both strong efficacy and acceptable safety, while any disappointment in the program could severely undermine the investment case. The company also faces meaningful execution risk from potential delays in R&D, regulatory, or commercial development, alongside intensifying competition in the mCRPC space that could limit future adoption and strategic flexibility. In addition, the need to secure sufficient capital for research, combined with product, supply chain, liquidity, partnership, legal, intellectual property, macroeconomic, and geopolitical risks, creates a highly uncertain fundamental profile.
This aggregate rating is based on analysts' research of Janux Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Janux Therapeutics (JANX) Analyst Forecast & Price Prediction
Start investing in Janux Therapeutics (JANX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Janux Therapeutics (JANX) Forecast
Janux Therapeutics (JANX) Analyst Forecast & Price Prediction
Start investing in Janux Therapeutics (JANX)
Order type
Buy in
Order amount
Est. shares
0 shares